Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors, Sodium Glucose Cotransporter 2 Inhibitors, or Sulfonylurea in the U.S. Food and Drug Administration’s Sentinel System

The risk of inflammatory bowel disease (IBD) following dipeptidyl peptidase-4 inhibitor (DPP4i) use remains uncertain. This poster summarizes a study that compared incident IBD risk among new users of DPP4i versus sodium-glucose co-transporter 2 inhibitors (SGLT2i) and sulfonylureas (SU) using claims data from six Data Partners of the U.S. FDA
Sentinel System from 2008 through 2024. It was presented at the 2025 ISPE Annual Meeting.